Table 1.
Participant Demographic and Clinical Characteristics by Protocol Completion.a
| Variable | Not Complete, n = 12 | Complete, n = 27 | Total, n = 39 | P Value |
|---|---|---|---|---|
| Age, mean (SD) | 56.5 (9.2) | 61.1 (5.4) | 59.7 (7.0) | .06 |
| Race | ||||
| White | 12 (16.7%) | 24 (66.7%) | 36 (92.3%) | 1.00 |
| Black | 0 (0%) | 2 (7.4%) | 2 (5.1%) | |
| Other | 0 (0%) | 1 (3.7%) | 1 (2.6%) | |
| Hispanic, Latino, or Spanish origin | 0 (0%) | 1 (3.7%) | 1 (2.6%) | 1.00 |
| Marital status | ||||
| Married | 9 (75.0%) | 17 (63.0%) | 26 (66.7%) | .49 |
| Divorced | 2 (16.7%) | 9 (33.3%) | 11 (28.2%) | |
| Widowed | 1 (8.3%) | 1 (3.7%) | 2 (5.1%) | |
| Education level | ||||
| High School or less | 2 (16.7%) | 1 (3.7%) | 3 (7.7%) | .33 |
| Some college/associate degree | 5 (41.7%) | 11 (40.7%) | 16 (41.0%) | |
| Bachelor’s degree or higher | 5 (41.7%) | 15 (55.6%) | 20 (51.3%) | |
| Employment status | ||||
| Full time | 4 (33.3%) | 10 (37%) | 14 (35.9%) | .15 |
| Part time | 0 (0.0%) | 3 (11.1%) | 3 (7.7%) | |
| Housework/child care | 2 (16.7%) | 0 (0.0%) | 2 (5.1%) | |
| Not working due to health | 3 (25.0%) | 3 (11.1%) | 6 (15.4%) | |
| Retired | 3 (25.0%) | 11 (40.7%) | 14 (35.9%) | |
| Income | ||||
| <$40 000 | 1 (8.3%) | 4 (14.8%) | 5 (12.8%) | .33 |
| $40 000-$70 000 | 2 (16.7%) | 9 (33.3%) | 11 (28.2%) | |
| >$70 000 | 9 (75.0%) | 11 (40.7%) | 20 (51.3%) | |
| Type of health insurance | ||||
| Private | 6 (50.0%) | 17 (63.0%) | 23 (59.0%) | .06 |
| Medicare | 3 (25.0%) | 9 (33.3%) | 12 (30.8%) | |
| Medi-gap | 0 (0.0%) | 1 (3.7%) | 1 (2.6%) | |
| Military | 3 (25.0%) | 0 (0.0%) | 3 (7.7%) | |
| Stage at diagnosis | ||||
| Stage I | 7 (63.6%) | 14 (51.9%) | 21 (55.2%) | .62 |
| Stage II | 2 (18.2%) | 9 (33.3%) | 11 (28.9%) | |
| Stage III | 2 (18.2%) | 4 (14.8%) | 6 (15.8%) | |
| Size of breast tumor, cm, mean (SD) | 1.6 (1.3) | 1.9 (1.5) | 1.8 (1.5) | .51 |
| Nodes evaluated, mean (SD) | 6.4 (6.7) | 6.3 (6.1) | 6.3 (6.2) | .96 |
| Nodes positive | ||||
| 0 | 7 (63.6%) | 20 (74.1%) | 27 (71.1%) | .62 |
| 1 | 1 (9.1%) | 1 (3.7%) | 2 (5.3%) | |
| 2 | 1 (9.1%) | 3 (11.1%) | 4 (10.5%) | |
| 4 | 1 (9.1%) | 1 (3.7%) | 2 (5.3%) | |
| 8 | 1 (9.1%) | 0 (0.0%) | 1 (2.6%) | |
| 11 | 0 (0.0%) | 1 (3.7%) | 1 (2.6%) | |
| 12 | 0 (0.0%) | 1 (3.7%) | 1 (2.6%) | |
| Positive estrogen receptor status | 11 (100.0%) | 27 (100.0%) | 38 (100.0%) | 1.00 |
| Positive progesterone receptor status | 10 (90.9%) | 22 (81.5%) | 32 (84.2%) | .65 |
| Positive HER2/neu receptor status | 2 (18.2%) | 5 (18.5%) | 7 (18.4%) | 1.00 |
| Included as primary treatment | ||||
| Lumpectomy | 6 (54.5%) | 21 (77.8%) | 27 (71.1%) | .24 |
| Mastectomy | 7 (63.6%) | 8 (29.6%) | 15 (39.5%) | .07 |
| Radiation therapy | 7 (63.6%) | 21 (77.8%) | 28 (73.7%) | .43 |
| Adjuvant chemotherapy | 6 (54.5%) | 6 (22.2%) | 12 (31.6%) | .07 |
| Neoadjuvant chemotherapy | 0 (0.0%) | 3 (11.1%) | 3 (7.9%) | .54 |
| Herceptin | 2 (18.2%) | 5 (18.5%) | 7 (18.4%) | 1.00 |
| Type of adjuvant hormone therapy | ||||
| Tamoxifen | 1 (9.1%) | 1 (3.7%) | 2 (5.3%) | .50 |
| Arimidex | 3 (27.3%) | 18 (66.7%) | 21 (55.3%) | .04 |
| Aromasin | 1 (9.1%) | 0 (0.0%) | 1 (2.6%) | 1.00 |
| Femara | 7 (63.6%) | 8 (29.6%) | 15 (39.5%) | .07 |
| Other | 1 (9.1%) | 0 (0.0%) | 1 (2.6%) | 1.00 |
Abbreviations: HER2, human epidermal growth factor receptor; SD, standard deviation.
a Protocol completion was defined as having completed both the baseline and the exit surveys, both blood draws and not missing more than 2 weekly surveys. The clinical questionnaire was not completed for 1 participant.